These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27892684)

  • 1. Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.
    Hua Y; Wang I; Liu B; Kelly DJ; Reid C; Liew D; Zhou Y; Wang BH
    Future Cardiol; 2017 Mar; 13(2):103-115. PubMed ID: 27892684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
    Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
    Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
    Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
    Vilela-Martin JF
    Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
    Singh JS; Lang CC
    Vasc Health Risk Manag; 2015; 11():283-95. PubMed ID: 26082640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
    Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
    Pham AQ; Patel Y; Gallagher B
    J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
    Gori M; Senni M
    Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LCZ696 : a new paradigm for the treatment of heart failure?
    Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
    Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
    Braunwald E
    J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Chrysant SG
    J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
    King JB; Bress AP; Reese AD; Munger MA
    Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
    Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
    Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    Vardeny O; Miller R; Solomon SD
    JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
    Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
    Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
    Mills J; Vardeny O
    Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.